Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. A copy of this slide presentation, dated January2019, is furnished as Exhibit99.1 to this Current Report on Form8-K. The information responsive to Item 7.01 of this Form8-K and Exhibit99.1 hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01 Other Events.
On January6, 2019, the Company issued a press release announcing its 2019 business objectives. The full text of this press release is filed as Exhibit99.2 to this Current Report on Form8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.
Item 7.01 Financial Statements and Exhibits.
Syros Pharmaceuticals, Inc. Exhibit
EX-99.1 2 a19-1318_1ex99d1.htm EX-99.1 Exhibit 99.1 An Expression Makes a World of Difference January 2019 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements,…
To view the full exhibit click
About Syros Pharmaceuticals,Inc. (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.